Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 5948
  • Home
  • Print this page
  • Email this page
Cover page of the Journal of Health Sciences
Year : 2018  |  Volume : 11  |  Issue : 3  |  Page : 207-214

Probiotic use in the management of hypertension: A new era of therapeutic management

1 Department of Pharmacology and Toxicology, B. V. Patel Pharmaceutical Education and Research Development Centre; Department of Pharmacology and Toxicology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
2 Sun Pharma Advanced Research Company Ltd., Vadodara, Gujarat, India
3 Department of Pharmacology and Toxicology, B. V. Patel Pharmaceutical Education and Research Development Centre, Ahmedabad, Gujarat, India

Correspondence Address:
Dr. Manish A Nivsarkar
B. V. Patel Pharmaceutical Education and Research Development Centre, S. G. Highway, Thaltej, Ahmedabad - 380 054, Gujarat
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/kleuhsj.kleuhsj_3_18

Rights and Permissions

Hypertension (HTN) has become a common chronic medical condition which affects ≥20% of adult population worldwide. HTN is assumed to be a major contributing factor for increasing complication of metabolic syndrome by adding one or more comorbidities such as heart disease, stroke, chronic renal failure, myocardial infarction, blindness, and dementia. HTN is also considered as a lifestyle disorder, and there are mainly two types of HTN, namely primary and secondary. Primary HTN is about 90%–95% of all cases of HTN and it is defined as high blood pressure due to genetic factors and nonspecific lifestyle, while secondary HTN is due to an identifiable cause such as Cushing's syndrome, obesity, and glucose intolerance. However, the exact cause and pathophysiology of HTN is still not clear. On the other hand, human body acts as a host and around 100 trillion bacteria are present in the body which is 10 times more than the number of cells in the human body. Many studies have published the role of microbiome in health and disease. Recent findings have shed light on the important role of microbiota in HTN and its treatment with probiotics (beneficial microbiota to host). Considering this, here, we have summarized and focused on possible interplays between the HTN microbiota, pharmacotherapeutic use of probiotics in HTN, and prospects to increase the degree of therapeutic personalization.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded377    
    Comments [Add]    
    Cited by others 3    

Recommend this journal